71.83
price down icon1.14%   -0.83
pre-market  Pre-market:  74.15   2.32   +3.23%
loading
Astrazeneca PLC stock is traded at $71.83, with a volume of 7.65M. It is down -1.14% in the last 24 hours and up +2.83% over the past month. AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$72.66
Open:
$72.725
24h Volume:
7.65M
Relative Volume:
1.69
Market Cap:
$222.77B
Revenue:
$54.98B
Net Income/Loss:
$7.77B
P/E Ratio:
28.85
EPS:
2.49
Net Cash Flow:
$9.14B
1W Performance:
+4.53%
1M Performance:
+2.83%
6M Performance:
+3.22%
1Y Performance:
-8.06%
1-Day Range:
Value
$71.49
$73.03
1-Week Range:
Value
$69.42
$74.38
52-Week Range:
Value
$61.24
$87.67

Astrazeneca PLC Stock (AZN) Company Profile

Name
Name
Astrazeneca PLC
Name
Phone
44 20 3749 5000
Name
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Name
Employee
61,100
Name
Twitter
@AstraZeneca
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
AZN's Discussions on Twitter

Compare AZN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Major icon
AZN
Astrazeneca PLC
71.83 225.28B 54.98B 7.77B 9.14B 2.49

Astrazeneca PLC Stock (AZN) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-15-25 Initiated Exane BNP Paribas Outperform
Feb-13-25 Upgrade UBS Neutral → Buy
Feb-12-25 Initiated Morgan Stanley Overweight
Nov-20-24 Upgrade UBS Sell → Neutral
Nov-06-24 Upgrade Deutsche Bank Sell → Hold
Sep-13-24 Downgrade Deutsche Bank Hold → Sell
May-30-24 Initiated Goldman Buy
Apr-16-24 Upgrade Deutsche Bank Sell → Hold
Feb-08-24 Downgrade Deutsche Bank Hold → Sell
Jan-23-24 Initiated Morgan Stanley Overweight
Jan-16-24 Resumed UBS Sell
Jan-03-24 Downgrade Jefferies Buy → Hold
Dec-18-23 Initiated HSBC Securities Buy
Sep-25-23 Upgrade Jefferies Hold → Buy
Jul-14-23 Initiated HSBC Securities Buy
Jul-12-23 Upgrade UBS Neutral → Buy
Jul-05-23 Downgrade Deutsche Bank Buy → Hold
Apr-11-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-05-23 Initiated BMO Capital Markets Outperform
Sep-15-22 Downgrade Credit Suisse Outperform → Neutral
Sep-07-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-29-22 Upgrade Argus Hold → Buy
Jun-14-22 Downgrade UBS Buy → Neutral
Feb-11-22 Upgrade DZ Bank Sell → Hold
Dec-07-21 Downgrade Jefferies Buy → Hold
Aug-12-21 Resumed JP Morgan Overweight
Apr-12-21 Downgrade Argus Buy → Hold
Mar-16-21 Upgrade Jefferies Hold → Buy
Feb-25-21 Upgrade UBS Neutral → Buy
Jan-15-21 Initiated Deutsche Bank Buy
Dec-07-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20 Upgrade UBS Sell → Neutral
Nov-11-20 Upgrade HSBC Securities Reduce → Hold
Sep-29-20 Initiated Berenberg Buy
Nov-22-19 Initiated SVB Leerink Outperform
Oct-25-19 Upgrade Liberum Hold → Buy
Apr-02-19 Downgrade UBS Neutral → Sell
Feb-05-19 Initiated Exane BNP Paribas Outperform
Jan-25-19 Upgrade Shore Capital Hold → Buy
Dec-11-18 Resumed Jefferies Hold
Oct-09-18 Initiated Guggenheim Buy
Aug-16-18 Downgrade Jefferies Buy → Hold
Mar-19-18 Upgrade Jefferies Hold → Buy
Feb-06-18 Reiterated Leerink Partners Mkt Perform
Feb-05-18 Reiterated Bernstein Outperform
Jan-18-18 Reiterated Leerink Partners Mkt Perform
Dec-29-17 Upgrade JP Morgan Neutral → Overweight
Oct-16-17 Upgrade Credit Suisse Neutral → Outperform
Sep-25-17 Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17 Upgrade Bernstein Mkt Perform → Outperform
View All

Astrazeneca PLC Stock (AZN) Latest News

pulisher
04:55 AM

Earnings Snapshot:AstraZeneca surpasses Q2 estimates;reaffirms FY outl - Seeking Alpha

04:55 AM
pulisher
04:19 AM

FTSE 100 rises on lift from AstraZeneca results - MarketScreener

04:19 AM
pulisher
03:44 AM

AstraZeneca's profit, revenue lifted by cancer drugs - The Edge Malaysia

03:44 AM
pulisher
03:08 AM

FTSE 100 Live: Mixed start to trading, Games Workshop impresses, AstraZeneca and Barclays less so - Proactive Investors

03:08 AM
pulisher
02:53 AM

AstraZeneca beats forecasts after record US growth - Financial Times

02:53 AM
pulisher
02:51 AM

AstraZeneca maintains outlook as pipeline delivers strong late-stage results - Proactive Investors

02:51 AM
pulisher
02:35 AM

Astrazeneca: Demand for cancer drugs boosts pharmaceutical giant - Yahoo.co

02:35 AM
pulisher
02:34 AM

FTSE 100 Live: London stocks set to rebound as AstraZeneca, Barclays, Entain report By Proactive Investors - Investing.com UK

02:34 AM
pulisher
02:28 AM

Shareholders of AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights – AZN - ACCESS Newswire

02:28 AM
pulisher
02:26 AM

FTSE 100 Live: London stocks set to rebound as AstraZeneca, Barclays, Entain report - Proactive Investors

02:26 AM
pulisher
02:25 AM

AstraZeneca Profit, Revenue Lifted by Cancer Drugs - Bloomberg

02:25 AM
pulisher
02:13 AM

AstraZeneca (AZN) Bets Big on U.S. with $50 Billion Manufacturing Expansion - MSN

02:13 AM
pulisher
02:10 AM

AstraZeneca beats second-quarter profit expectations, maintains outlook - Reuters

02:10 AM
pulisher
02:06 AM

AstraZeneca beats second-quarter profit expectations - MarketScreener

02:06 AM
pulisher
02:05 AM

AstraZeneca beats profit expectations on robust drug sales, U.S. demand - Yahoo.co

02:05 AM
pulisher
01:37 AM

AstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of Gefurulimab - Insider Monkey

01:37 AM
pulisher
Jul 28, 2025

AstraZeneca’s NIAGARA-2 Study: A New Frontier in Bladder Cancer Treatment - TipRanks

Jul 28, 2025
pulisher
Jul 28, 2025

AstraZeneca’s ARTEMIDE-Lung02: A New Phase III Study in Lung Cancer Treatment - TipRanks

Jul 28, 2025
pulisher
Jul 28, 2025

AstraZeneca’s Fasenra Study: Monitoring Real-World Safety and Effectiveness - TipRanks

Jul 28, 2025
pulisher
Jul 28, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tempus AI, Inc. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.

Jul 28, 2025
pulisher
Jul 28, 2025

AstraZeneca gets FDA priority review for Imfinzi application - Seeking Alpha

Jul 28, 2025
pulisher
Jul 28, 2025

What makes AstraZeneca PLC Depositary Receipt stock price move sharplyDiscover undervalued stocks before they soar - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Trending tickers: Palantir, Samsung, Heineken, Volkswagen and AstraZeneca - Yahoo.co

Jul 28, 2025
pulisher
Jul 28, 2025

Here’s where the AstraZeneca share price could end the year - MSN

Jul 28, 2025
pulisher
Jul 28, 2025

What is the dividend policy of AstraZeneca PLC Depositary Receipt stockDiscover high-impact stocks for growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

What institutional investors are buying AstraZeneca PLC Depositary Receipt stockBreakthrough financial growth - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How does AstraZeneca PLC Depositary Receipt compare to its industry peersAchieve explosive financial results today - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

AstraZeneca’s (AZN) Dividend: Resilient, Predictable, and Built on Innovation - MSN

Jul 27, 2025
pulisher
Jul 26, 2025

AstraZeneca’s Osimertinib Study: A Potential Game-Changer for NSCLC Treatment - The Globe and Mail

Jul 26, 2025
pulisher
Jul 26, 2025

AstraZeneca’s New Trial: A Potential Game-Changer in Prostate Cancer Treatment - The Globe and Mail

Jul 26, 2025
pulisher
Jul 26, 2025

AstraZeneca’s AZD4144 Study Completion: Key Insights for Investors - The Globe and Mail

Jul 26, 2025
pulisher
Jul 26, 2025

AstraZeneca’s AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment - The Globe and Mail

Jul 26, 2025
pulisher
Jul 26, 2025

AstraZeneca’s Latest Study: Evaluating Ceralasertib’s Impact on Cancer Drug Pharmacokinetics - The Globe and Mail

Jul 26, 2025
pulisher
Jul 25, 2025

Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

Bristol Appoints AstraZeneca’s Massacesi As Next CMO - insights.citeline.com

Jul 25, 2025
pulisher
Jul 25, 2025

What drives AstraZeneca PLC Depositary Receipt stock priceFree Stock Selection - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

AstraZeneca PLC Depositary Receipt Stock Analysis and ForecastFree Market Dynamics Reports - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

AstraZeneca (AZN) Sees Increased Bullish Option Activity - GuruFocus

Jul 25, 2025
pulisher
Jul 25, 2025

AstraZeneca’s MAGELLAN Study: A New Horizon in NSCLC Treatment - The Globe and Mail

Jul 25, 2025
pulisher
Jul 25, 2025

AstraZeneca’s Promising Phase 2 Study on Trastuzumab Deruxtecan for HER2 Tumors - The Globe and Mail

Jul 25, 2025
pulisher
Jul 25, 2025

AstraZeneca and Amgen’s Phase III COPD Study: Market Implications - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Eli Lilly and AstraZeneca’s Promising Phase 3 Study on KRAS G12C-Mutant NSCLC - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

AstraZeneca’s NT-175 Study: A New Frontier in Cancer Treatment - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

AstraZeneca’s Latest Study on Acalabrutinib: A Potential Game Changer for CLL Patients with Heart Conditions - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

AstraZeneca’s eVOLVE-02 Study: A New Frontier in Cancer Treatment - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

AstraZeneca’s Phase III Study on AZD0780: A Potential Game-Changer for Cholesterol Management - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

AstraZeneca’s ASTER Study: Real-World Insights into Anifrolumab for SLE - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

AstraZeneca’s Phase 3 Trial: A New Hope for Advanced Biliary Tract Cancer Treatment - The Globe and Mail

Jul 25, 2025
pulisher
Jul 25, 2025

AstraZeneca’s ARTEMIDE-Lung04 Study: A New Hope for mNSCLC Treatment? - The Globe and Mail

Jul 25, 2025
pulisher
Jul 25, 2025

AstraZeneca’s RACE-2L Study: Real-World Insights into NSCLC Treatment - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

AstraZeneca’s PROVIDENCE Study: Advancing Breast Cancer Treatment with Real-World Insights - TipRanks

Jul 25, 2025

Astrazeneca PLC Stock (AZN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
Cap:     |  Volume (24h):